Rituximab Market Size & Share, by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Application (Blood Cancer, Rheumatoid Arthritis, Wegener Granulomatosis) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3315
  • Published Date: Sep 01, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Rituximab Market size is poised to cross 10 Billion by the end of 2035, growing at a CAGR of 16 % during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of rituximab was over USD 3 Billion. The increasing incidences of non-Hodgkin’s lymphoma (NHL) are expected to boost the market growth of rituximab. As per the American Cancer Society, NHL is one of the most common diseases in the USA. Around 77,200 cases were registered in 2020 in the US, the incidences are anticipated to grow rapidly due to the rising cases of cancer in the region.

In case of an autoimmune disease, the immune system attacks the healthy cells of the body. Thus, the rising prevalence of autoimmune diseases is likely to accelerate the growth of the rituximab market. According to the reports by University of Oxford, about 22 million are affected by autoimmune diseases yearly. These factors are bolstering the market growth of rituximab.

Rituximab Market
Get more information on this report: Request Free Sample PDF

Rituximab Market: Key Insights

Base Year


Forecast Year



~ 16%

Base Year Market Size (2022)

~ USD 3 Billion

Forecast Year Market Size (2035)

~ USD 10 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Rituximab Sector: Growth Drivers and Challenges


Growth Drivers

  • Increasing Demand for Monoclonal Antibodies – rituximab is one of the most common monoclonal antibodies used in the treatment of cancer, cardiovascular diseases and others. Also, the survival rate has increased with the application of rituximab with chemotherapy. In addition to this the rising cases of these diseases are boosting the market growth rapidly.
  • Increasing collaborations for the development of new products – In collaboration with other companies operating in the sector, the companies operating in the biosimilars sector continue to focus on the development of new products. The rituximab biosimilar market has been shaped by innovative partnerships. For example, in May 2020, Teva Pharmaceutical Industries Ltd and Celltrion Healthcare Co. Ltd jointly launched a biosimilar of TruximaNumab injection to treat polyangiitis and Rheumatoid Arthritis in the US market.
  • Investment in the healthcare sector - Over the last 15 years, the U.S. is the world's largest contributor to Global Health funding, and its investment in Global Health has increased substantially over time. Additionally, US healthcare spending increased 2.7% in 2021. The Cancer Moonshot, the US cancer plan, is mobilizing efforts to achieve two very important goals set by the President of the United States: Preventing over four million deaths from cancer within 2047 as well as improving the way people who are affected by cancer experience it. Investment and funding in healthcare is positively driving the growth of rituximab market.


  • High-Cost of Rituximab - The major challenge to the growth of the rituximab market over the next few years will be the high costs associated with these biosimilars. Compared to IV biosimilar rituximab, the cost of the subcutaneous option was higher.
  • Severe Side Effects
  • Production Complexities

Rituximab Segmentation

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

The hospital pharmacies segment in the rituximab market is expected to garner the largest revenue during the forecast period. Due to the growing use of rituximab for cancer therapy in hospitals, the hospital pharmacies segment is expected to account for a total market share of 39.7% by 2035. The dominant position of the sector is expected to be achieved during the forecast period by rising healthcare spending around the world, increased awareness levels for patients, and availability of superior hospital infrastructure in high-income countries.

Application (Blood Cancer, Rheumatoid Arthritis, Wegener’s Granulomatosis)

The blood cancer segment is expected to hold 24% share of the global rituximab market by 2035. Nearly every 3 minutes, one person in the US is diagnosed with blood cancer. Leukaemia was the sixth most frequent cause of cancer deaths in men from 2013 to 2017 and the seventh most frequent cause in women in the US. Also, the increased funding and investment in healthcare mostly in cancer is driving the growth of the market. The cases associated with blood cancer are expected to increase in the upcoming years due to lifestyle factors which will significantly boost the market growth of rituximab.

Our in-depth analysis of the global market includes the following segments:

     Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies


  • Blood Cancer
  • Rheumatoid Arthritis
  • Wegener’s Granulomatosis

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Rituximab Industry - Regional Synopsis

North American Market Forecast

North America rituximab market is expected to hold the largest revenue share during the forecast period. Due to the fact that North America has a very advanced healthcare infrastructure, higher patient knowledge, and increasing cancer research prospects, it is estimated to account for an overall market share of 46.1% by 2035. In addition, market growth is expected to be fuelled by increased government spending on cancer research as well as the presence of major pharmaceutical companies such as Pfizer Inc., Amgen Inc., and Merck & Co.

APAC Market Statistics

The Asia Pacific region is expected to hold the second-largest position in the rituximab market. In view of rising disposable incomes, availability of a large patient population for monoclonal antibody cancer treatments, and increased focus on healthcare, the Asia Pacific region is expected to show the highest growth rate during the forecast period at 12.1%. As well as providing investment opportunities in clinical research, countries such as India and China are expected to have a positive impact on the R&D prospects for monoclonal antibodies.

Research Nester
Rituximab Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Rituximab Landscape

    • Amgen Inc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Henlius Biotech, Inc.
    • Nordic Nanovector ASA
    • Biocon Biologics Ltd
    • Pfizer Inc.
    • Chugai Pharmaceuticals
    • Zenyaku Kogyo Co. Ltd,
    • SymBio Pharmaceuticals
    • Daiichi Sankyo
    • Kyowa Kirin Co. Ltd


In The News

  • Nordic Nanovector ASA announced the successful outcomes of the Archer-1 phase B trial for treating second-line follicular lymphoma (2L FL), investing Betalutin (177Lu lilotomab satetraxetan) in combination with rituximab (RTX).
  •  Biocon Biologics Ltd has signed an agreement with the Clinton Health Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP).

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3315
  • Published Date: Sep 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for monoclonal antibodies, increasing collaborations for the development of new products and investment in healthcare sector.

The market size of rituximab is anticipated to attain a CAGR of 16% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Amgen Inc, Henlius Biotech, Inc., Nordic Nanovector ASA, Biocon Biologics Ltd., Pfizer Inc., Chugai Pharmaceuticals, Zenyaku Kogyo Co. Ltd, SymBio Pharmaceuticals, Daiichi Sankyo, Kyowa Kirin Co. Ltd, and others.

The blood cancer segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Rituximab Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying